Stockreport

ArriVent BioPharma Reports Third Quarter 2024 Financial Results [Yahoo! Finance]

ArriVent BioPharma, Inc.  (AVBP) 
PDF Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash e [Read more]